CANF
Can-Fite Biopharma Ltd (CANF)
Healthcare • NYSE MKT • $3.51-0.85%
- Symbol
- CANF
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $3.51
- Daily Change
- -0.85%
- Market Cap
- $7.52M
- Trailing P/E
- N/A
- Forward P/E
- -4.81
- 52W High
- $23.40
- 52W Low
- $2.83
- Analyst Target
- $50.00
- Dividend Yield
- N/A
- Beta
- 0.03
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine…
Company websiteResearch CANF on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.